Has the pharma company’s high-throughput screening bet paid off?
By Aaron J. Sender
Berta Strulovici was faced with a choice. When she joined Merck five years ago from Tularik to head its high-throughput screening operations, the pharmaceutical company had no centralized screening facility. “That was my mandate,” she says.